Search - tctmd.com

Displaying 241 - 260 of 401

Sort: Relevancy | Date

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Inclisiran Data in NEJM Prompt Talk of What Comes Next

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

March 24, 2020

News Daily News

COVID-19 Should Not Guide Use of ACE Inhibitors/ARBs, Heart Societies Say

March 17, 2020

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

March 10, 2020

Intensive BP Control Lengthens Life: SPRINT Analysis

News Daily News

Intensive BP Control Lengthens Life: SPRINT Analysis

March 03, 2020

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

February 26, 2020

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

February 07, 2020

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Daily News

Many ASCVD Patients Skimp on CV Meds Due to Costs: US Survey

November 25, 2019

Grief and CVD: Simple Regimen May Lower Risk

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

November 19, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.